
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp is positioned favorably due to its strong performance in the Healthcare/Life Sciences sector, which generated $424 million in revenue for FQ4, reflecting a 2% year-over-year increase and expected growth of 9.6% year-over-year in FQ1, indicating a robust recovery in customer demand. The Aerospace and Defense segment is also anticipated to show growth, with quarterly revenue expected to rise by mid-single digits, driven largely by program ramps related to commercial air and unmanned aircraft sectors. Overall, Plexus expects a company-wide revenue growth goal of 9-12% for fiscal year 2026, supported by strategic initiatives and multiple program implementations, suggesting a positive outlook for its financial trajectory.
Bears say
Plexus Corp experienced a decline in gross margin, dropping to 9.9% from 10.1% in the previous quarter, alongside a decrease in revenue from the Aerospace & Defense segment, which fell by 6% quarter-over-quarter and year-over-year. The company has expressed expectations for a further decline in Industrial revenues in the upcoming quarter, attributed to seasonality and moderating demand, although modest growth is anticipated for the following fiscal year due to strength in semiconductor capital equipment. Additionally, broader economic conditions, including signs of a potential economic slowdown and company-specific risks such as manufacturing disruptions and challenges in maintaining competitiveness, contribute to a negative outlook for Plexus's stock.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares